Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 2,021
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
52% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 44
28% more capital invested
Capital invested by funds: $5.05B [Q1] → $6.47B (+$1.42B) [Q2]
11% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 114
6% more funds holding
Funds holding: 338 [Q1] → 358 (+20) [Q2]
4.31% more ownership
Funds ownership: 96.01% [Q1] → 100.33% (+4.31%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
30% less call options, than puts
Call options by funds: $89.1M | Put options by funds: $126M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
BTIG
Mark Massaro
|
$70
|
Buy
Maintained
|
4 Sep 2025 |
|
Scotiabank
Sung Ji Nam
|
$60
|
Sector Outperform
Maintained
|
31 Jul 2025 |
|
Raymond James
Andrew Cooper
|
$61
|
Outperform
Maintained
|
31 Jul 2025 |
Financial journalist opinion
Based on 7 articles about GH published over the past 30 days
